GlassScriptPhysician profile
Darshini Shah
NPI 1013533017
$606.05
in general payments reported to CMS, 2019-2025
17 companies · $322 in 2025
The $322 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $39.83 · 2024: $245 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $606.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $103.37 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $63.94 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Amneal Pharmaceuticals LLC | $62.96 | 2024-2025 | Crexont |
| Exact Sciences Corporation | $43.33 | 2024-2025 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $43.13 | 2024 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $41.94 | 2023-2025 | |
| Merz Pharmaceuticals, LLC | $35.84 | 2025 | Xeomin, Inbrija |
| Dynavax Technologies Corporation | $35.42 | 2024-2025 | Heplisav-B |
| Merck Sharp & Dohme LLC | $31.36 | 2025 | Verquvo, Capvaxive |
| Spr Therapeutics, INC | $22.17 | 2025 | Sprint Pns System |
| Alexion Pharmaceuticals, INC. | $20.30 | 2023 | Strensiq |
| Eisai INC. | $19.00 | 2025 | |
| Azurity Pharmaceuticals, INC. | $18.90 | 2025 | Horizant |
| Cycle Pharmaceuticals INC | $18.88 | 2024 | Tascenso Odt |
| Astrazeneca Pharmaceuticals LP | $16.23 | 2024 | Farxiga |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $16.05 | 2025 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $13.23 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darshini Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.